Eric J Moore1, Kathryn M Van Abel1, Daniel L Price1, Christine M Lohse2, Kerry D Olsen1, Ryan S Jackson3, Eliot J Martin1. 1. Department of Otolaryngology - Head and Neck Surgery, Mayo Clinic School of Medicine, Rochester, Minnesota. 2. Department of Health Sciences Research, Mayo Clinic School of Medicine, Rochester, Minnesota. 3. Department of Otolaryngology - Head and Neck Surgery, Washington University, St Louis, Missouri.
Abstract
BACKGROUND: This study presents oncologic outcomes after transoral robotic surgery (TORS) ± adjuvant therapy for oropharyngeal squamous cell carcinoma (SCC). METHODS: Three hundred fourteen patients undergoing TORS ± adjuvant therapy for oropharyngeal SCC from May 1, 2007, to May 31, 2015, are analyzed. RESULTS: Median follow-up was 3.3 years (interquartile range [IQR] 1.8-5.3 years; range 1 day to 9.3 years). Estimated locoregional recurrence-free survival, distant metastasis-free survival (DMFS), overall survival (OS), and cancer-specific survival (CSS) rates (95% confidence interval [CI] number still at risk) at 5 years after surgery were 92% (88-95; 92), 90% (86-94; 92), 86% (82-92; 98), and 94% (91-97; 98), respectively. Negative margins were achieved in 98% of cases. The adult comorbidity evaluation (ACE)-27 comorbidity index, human papillomavirus (HPV) status, pathologic N classification, and number of attempts to clear margins were associated with death due to cancer (P = .003, P = .002, P = .030, and P = .002, respectively). CONCLUSION: The need to take ≥2 margins to achieve resection portends an increased risk of locoregional recurrence and death due to disease in oropharyngeal SCC.
BACKGROUND: This study presents oncologic outcomes after transoral robotic surgery (TORS) ± adjuvant therapy for oropharyngeal squamous cell carcinoma (SCC). METHODS: Three hundred fourteen patients undergoing TORS ± adjuvant therapy for oropharyngeal SCC from May 1, 2007, to May 31, 2015, are analyzed. RESULTS: Median follow-up was 3.3 years (interquartile range [IQR] 1.8-5.3 years; range 1 day to 9.3 years). Estimated locoregional recurrence-free survival, distant metastasis-free survival (DMFS), overall survival (OS), and cancer-specific survival (CSS) rates (95% confidence interval [CI] number still at risk) at 5 years after surgery were 92% (88-95; 92), 90% (86-94; 92), 86% (82-92; 98), and 94% (91-97; 98), respectively. Negative margins were achieved in 98% of cases. The adult comorbidity evaluation (ACE)-27 comorbidity index, human papillomavirus (HPV) status, pathologic N classification, and number of attempts to clear margins were associated with death due to cancer (P = .003, P = .002, P = .030, and P = .002, respectively). CONCLUSION: The need to take ≥2 margins to achieve resection portends an increased risk of locoregional recurrence and death due to disease in oropharyngeal SCC.
Authors: Daniel J Ma; Katharine A Price; Eric J Moore; Samir H Patel; Michael L Hinni; Joaquin J Garcia; Darlene E Graner; Nathan R Foster; Brenda Ginos; Michelle Neben-Wittich; Yolanda I Garces; Ashish V Chintakuntlawar; Daniel L Price; Kerry D Olsen; Kathryn M Van Abel; Jan L Kasperbauer; Jeffrey R Janus; Mark Waddle; Robert Miller; Satomi Shiraishi; Robert L Foote Journal: J Clin Oncol Date: 2019-06-04 Impact factor: 44.544
Authors: Xiaotian Wu; David A Pastel; Rihan Khan; Clifford J Eskey; Yuan Shi; Michael Sramek; Joseph A Paydarfar; Ryan J Halter Journal: Ann Biomed Eng Date: 2022-01-07 Impact factor: 4.219
Authors: Anthony T Nguyen; Michael Luu; Jon Mallen-St Clair; Alain C Mita; Kevin S Scher; Diana J Lu; Stephen L Shiao; Allen S Ho; Zachary S Zumsteg Journal: JAMA Oncol Date: 2020-10-01 Impact factor: 31.777
Authors: G Meccariello; F Montevecchi; G D'Agostino; G Iannella; S Calpona; E Parisi; M Costantini; G Cammaroto; R Gobbi; E Firinu; R Sgarzani; D Nestola; C Bellini; A De Vito; E Amadori; C Vicini Journal: Acta Otorhinolaryngol Ital Date: 2019-04 Impact factor: 2.124